Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2023-03-01 DOI:10.1016/j.beha.2023.101446

Jeremy Rubinstein , Keri Toner , Thomas Gross , Birte Wistinghausen

引用次数: 4

Abstract

Post-transplant Lymphoproliferative Disease (PTLD) remains a major complication of solid organ transplantation (SOT) in pediatric patients. The majority are Epstein-Barr Virus (EBV) driven CD20⁺ B-cell proliferations responsive to reduction to immunosuppression and anti-CD20 directed immunotherapy. This review focusses on the epidemiology, role of EBV, clinical presentation, current treatment strategies, adoptive immunotherapy and future research in EBV + PTLD in pediatric patients.

查看原文本刊更多论文

儿童、青少年和年轻人实体器官移植后淋巴细胞增生性疾病的诊断和治疗

移植后淋巴增生性疾病（PTLD）仍然是儿童实体器官移植（SOT）的主要并发症。大多数是EB病毒（EBV）驱动的CD20+B细胞增殖，对免疫抑制和抗CD20定向免疫疗法的减少有反应。本文综述了儿童EBV+PTLD的流行病学、EBV的作用、临床表现、目前的治疗策略、过继免疫疗法以及未来的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.